Sangamo Therapeutics (SGMOQ) Receivables - Other (2010 - 2024)

Sangamo Therapeutics' Receivables - Other history runs 15 years deep, the most recent figure standing at $10.0 million for Q3 2024.

• On a quarterly basis, Receivables - Other rose 1561.13% year-over-year to $10.0 million in Q3 2024; TTM through Sep 2024 was $10.0 million, a 1561.13% increase from a year earlier, with the FY2023 full-year figure at $403000.0, down 49.24% from the prior year.
• Receivables - Other rose to $10.0 million in Q3 2024 per SGMOQ's latest filing, from $403000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $10.0 million in Q3 2024 and bottomed at $289000.0 in Q2 2022.
• The 5-year median for Receivables - Other is $794000.0 (2022), against an average of $1.3 million.
• Across the five-year window, Receivables - Other plunged 66.28% in 2021 and jumped 1561.13% in 2024, its largest moves.
• Year by year, Receivables - Other stood at $1.0 million in 2020, then slumped by 66.28% to $349000.0 in 2021, then jumped by 127.51% to $794000.0 in 2022, then plunged by 49.24% to $403000.0 in 2023, then jumped by 2381.39% to $10.0 million in 2024.
• Per Business Quant, the three latest SGMOQ Receivables - Other figures stand at $10.0 million (Q3 2024), $403000.0 (Q4 2023), and $602000.0 (Q3 2023).